Click here to search courses using NAPNAP's previous Course Catalog layout.

Title
Category
Credits
Event date
Cost
  • Primary Care
  • Pharmacology CE
  • 0.25 Contact hours
$2.50
0.25 NAPNAP Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $0 for NAPNAP Members. For non-members, this continuing education activity rate is $2.50. 
  • Primary Care
  • FREE for Members
  • Infectious Disease
  • Pharmacology CE
  • 1.00 Contact hours
$0.00
1.0 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and non-members. Diagnosing tick-borne diseases (TBDs), whether known or emerging, can be confounding and complex. Timely and correct diagnosis can be essential, since some TBDs can be quickly fatal or have lasting sequelae if left untreated. This presentation will cover symptoms, CDC guidance for treatment, as well as appropriate communication with parents and colleagues. It will also include the vectors, geography of tick-borne diseases, risk, and bite avoidance strategies.
  • Mental Health
  • Pharmacology CE
  • Psychopharmacology CE
  • 1.00 Contact hours
$20.00
1.0 NAPNAP contact hour, of which 1.0 is Pharmacology and 1.0 Psychopharmacology. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non- members, this continuing education activity rate is $20. An extensive review will provide the participant with up-to-date information about commonly used antidepressants and atypical antipsychotics.
  • Primary Care
  • Acute Care
  • Pharmacology CE
  • 1.00 Contact hours
$20.00
1.0 NAPNAP Pharmacology Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non- members, this continuing education activity rate is $20. This course will review the definition and regulation of the use of biologic agents in children and adolescents.
  • Primary Care
  • Acute Care
  • Pharmacology CE
  • 1.25 Contact hours
$25.00
1.25 NAPNAP Pharmacology Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $12.50 for NAPNAP Members. For non- members, this continuing education activity rate is $25. An extensive review will provide the participant with up-to-date information pharmacological management of common respiratory illnesses in children.
  • Primary Care
  • Acute Care
  • Infectious Disease
  • Pharmacology CE
  • 1.00 Contact hours
$20.00
1.0 NAPNAP Pharmacology Contact Hour. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non- members, this continuing education activity rate is $20. Current information from CDC will be reviewed. Most current information about vaccine safety will also be covered.
  • Primary Care
  • FREE for Members
  • Pharmacology CE
  • 1.00 Contact hours
$0.00
1.0 NAPNAP contact hour of which 0.25 contain pharmacology content. This continuing education activity is offered FREE to Members and Nonmembers. The purpose of this program is to inform primary care pediatric health care providers about the management of children and adolescents with obesity guided by the American Academy of Pediatrics (AAP) Clinical Practice Guidelines published in 2023. The presentation content focuses on how to implement best practices for the management of children and adolescents with obesity including pharmacotherapy. Additionally, guidance on the AAP resources and how to access and utilize these tools will be discussed.
  • Primary Care
  • Pharmacology CE
  • Pharmacology
  • 1.25 Contact hours
$25.00
1.25 NAPNAP Contact Hour of which 0.5 contain pharmacology content. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $12.5 for NAPNAP Members. For non-members, this continuing education activity rate is $25. This course is an archived session from NAPNAP's Pediatric Virtual Symposium: 2024 Targeted Topics. Dyslipidemia is a modifiable risk factor for cardiovascular disease. There are specific lipid screening recommendations for pediatric patients, especially for those with diabetes. This presentation will provide an overview of dyslipidemia management in pediatrics.
  • Pharmacology CE
  • Pharmacology
  • 1.00 Contact hours
$20.00
1.00 NAPNAP Contact Hour of which 1.00 contain pharmacology content. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non-members, this continuing education activity rate is $20. This course is an archived session from NAPNAP's Pediatric Virtual Symposium: 2024 Targeted Topics. Immunosuppression is required for successful solid organ transplantation. This presentation will introduce the major types of immunosuppressive medications, when the different medications are introduced and for how long, and why certain immunosuppressants are used in different clinical situations.
  • Primary Care
  • Pharmacology CE
  • Pharmacology
  • 1.00 Contact hours
$20.00
1.00 NAPNAP Contact Hour of which 0.5 contain pharmacology content. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non-members, this continuing education activity rate is $20. This course is an archived session from NAPNAP's Pediatric Virtual Symposium: 2024 Targeted Topics. The cannabis plant contains more than 60 pharmacologically active substances that can impact almost every body system. Nurse practitioners must be knowledgeable on the different cannabis preparations available, common usage and physiological impact on health. It is also imperative that health care providers know the best terms and communication approaches to ask young patients about their use of cannabis and assess willingness for cessation.